38 results about "Plant Lectins" patented technology

The invention discloses a method for industrially preparing a white kidney bean Alpha-amylase inhibitor, and belongs to the field of the plant active ingredient preparation. The method comprises the following steps: firstly peeling white kidney beans by a dry method, dry-smashing, sieving and preparing bean flour, and extracting the bean flour by using water, collecting slurry after centrifuging,after performing adequate enzymolysis on the slurry by using Beta-amylase, to obtain enzymatic hydrolysate, filtering the enzymatic hydrolysate by using a ceramic film, performing ultrafiltration on obtained filtrate by using 80-150 kDa of an ultrafiltration membrane, performing the ultrafiltration on penetrated liquid by using 15-30 kDa of the ultrafiltration membrane, spray-drying trapped fluid,to obtain the white kidney bean Alpha-amylase inhibitor. The prepared white kidney bean Alpha-amylase inhibitor product is high in Alpha-amylase inhibitor activity, no starch, and no phytolectin andtrypsin inhibitor activity, and has the reliable physiological efficacy and safety. In addition, the preparation technology is green and environmental, capable of adapting the requirements of the modern industrial production, and has the remarkable economic benefit and the social benefit.

A compound preparation for human external use and its application belong to the technical field of human preparations. The lectin and the white fungus polysaccharide are used as active components, and the relative weight ratio between the two active components contained in the preparation is: 0.5-1.0 parts of the lectin and 1.5-3.0 parts of the white fungus polysaccharide. Said lectin is preferably kidney bean lectin. The dosage form is preferably a gel solution. 100ml of the gel solution contains 0.5-1.0 grams of plant lectin, 1.5-3.0 grams of tremella polysaccharide, 0.8-0.9 grams of NaCl, and pH buffers, stabilizers, and preservatives. The preparation is mainly used for external use by humans during sexual behavior, and it also has the functions of contraception, prevention and treatment of sexually transmitted diseases and lubrication; it can also be used as skin care products. Its principle of action is brand new and will not affect the human endocrine system; it can interfere and prevent HIV and other pathogens from invading normal cells in the body; it is extremely safe.

The present application aims at providing a treatment method effective for various cancers, immune deficiency diseases and infections, and a method of proliferating / activating cells associated therewith, which can be performed at such low costs that the methods can be applicable to nonhuman animals. A method of proliferating / activating cells of the present application comprises steps of, during the cell culture, supplementing a plant lectin (such as concanavalin A) and a growth factor having interleukin-2-like activity to the culture medium. Accordingly, the present method can proliferate / activate, on a preferential basis, a-type T cells associated with cell-mediated immunity for cancers, immunodeficiency diseases and infectious diseases.

The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.

The invention discloses a method for quantitatively detecting the coagulant activity of bean phytohemagglutinin and belongs to the technical field of plant component detection. According to the method, a red cell suspension for detection is subjected to cell quantification; meanwhile, a coagulant activity concentration standard curve is drawn by using the bean phytohemagglutinin with the known concentration as a standard substance, and the coagulant activity concentration of the bean phytohemagglutinin is further calculated, so that the coagulant activity of the bean phytohemagglutinin is quantified.

The invention provides a method of increasing an immune response in a mammal. The method involves administering to the mammal an admixture comprising an immunogen and a plant lectin. The plant lectin acts as an adjuvant to increase an immune response against the immunogen. The method is especially well-suited for mucosal administration to humans and other mammals.

The invention relates to the detection of protein glycosyl, in particular to an application of a compound as a blocking reagent for glycosyl on an antibody. To solve the problem of the interference ofthe glycosyl of a current antibody on detection, a compound used as a blocking reagent for the glycosyl on the antibody is provided, and the compound is selected from one of alpha-semicarbazide, acetylhydrazine, sulfur acetohydrazide, thiosemicarbazide, asparagine hydrazide, tyrosine hydrazine, N (benzyloxycarbonyl)-L-valyl-L-tyrosine hydrazide, or N (benzyloxycarbonyl) glycinic hydrazide. The compound used as the blocking reagent for the glycosyl on the antibody has the advantages of being capable of conducting petreatment of antibodies, avoiding binding of plant lectins to antibodies, guaranteeing accurate quantification of the glycosyl on captured proteins, being simple in the process of blocking the antibodies with one step reaction needed, shortening the reaction process of existingblocked antibodies, and significantly reducing costs.

The invention relates to the technical field of plant extraction, and discloses a method for extracting L-type and E-type phytohemagglutinins (PHAs). According to the method, crude protein extraction is carried out through the steps of soaking, crushing, centrifuging, ammonium sulfate fractional precipitation and the like on beans, and then L-type and E-type PHAs are separated and purified through hydrophobic chromatography and ion exchange chromatography. The method is simple to operate, and the extracted L-type and E-type PHAs are high in purity and suitable for large-scale production of the L-type and E-type PHAs.

Described is a matrix to identify mother's milk missing fucosyltransferase-2 (FUT2) dependent glycans which comprise a line of a glycan binding protein such as a lectin or antibody suitable to bind 2'fucosyl-glycans and a line of a positive control to bind a mother's milk protein. For instance, this matrix is porous and allows for transport by capillary force of compounds of mother's milk such asglycoproteins. Especially, the glycan binding protein is the plant lectin from Ulex europaeus. A diagnostic kit comprising one or more of such matrices and a device suitable to receive such a matrix provided with a milk application window and a read-out window has been described as well. Finally a kit-of-parts comprising such a diagnostic kit and one or more feeding doses of 2'fucosyl-glycans hasbeen disclosed.

The invention discloses a phytolectin succ-Con A for treating corona virus infection and an application thereof. The invention discovers that the phytolectin succ-Con A has a broad-spectrum antiviral effect on SARS-CoV-2 and SARS-CoV-2 mutant strains, SARS-CoV and MERS-CoV corona virus strains at the same time for the first time, and can be used as a broad-spectrum antiviral preparation or drug active ingredient. A new thought is provided for preventing and treating corona virus infection.

The invention provides fusion protein for improving insect resistance of plants and an application thereof. Specifically, the invention provides fusion protein for improving insect resistance of plants. The fusion protein comprises the following structure: a neuropeptide AaIT element and a phytolectin element. The fusion protein can effectively improve the insect resistance of transgenic plants, particularly the resistance to piercing-sucking insects.

The subject invention concerns materials and methods for treating or preventing disease and conditions associated with various sulfatase enzymes that are defective or that are not properly expressed in a person or animal. In one embodiment, the disease is Sanfilippo A (MPS-IIIA) disease. The subject invention also concerns materials and methods for treating or preventing multiple sulfatase deficiency (MSD) in a person or animal. Compounds of the invention include a fusion protein comprising i) a mammalian sulfatase, or an enzymatically active fragment or variant thereof, and ii) a plant lectin or a binding subunit thereof. In a specific embodiment, the mammalian sulfatase is a human sulfatase, or an enzymatically active fragment or variant thereof. Polynucleotides encoding the fusion proteins are also contemplated for the subject invention. The subject invention also concerns materials and methods for producing proteins of the invention.

The current invention involves the use of protein lectins produced by plants including the non-toxic carbohydrate binding subunits (B subunits) of plant “AB toxins” (PTB lectins) as delivery vehicles for mobilizing associated drug substances for delivery to animal and human cells. The resulting protein fusions or conjugates retain lectin carbohydrate specificity for binding to cells and cellular trafficking activity so as to deliver an associated drug compound to the site of disease manifestation. One embodiment of this invention concerns the ability of ricin toxin B subunit, as a model PTB lectin, to deliver enzyme replacement therapeutic drugs to cells of several organs of the body including the brain and central nervous system, eyes, ears, lungs, bone, heart, kidney, liver, and spleen for treating lysosomal diseases.

The present application aims at providing a treatment method effective for various cancers, immune deficiency diseases and infections, and a method of proliferating / activating cells associated therewith, which can be performed at such low costs that the methods can be applicable to nonhuman animals.A method of proliferating / activating cells of the present application comprises steps of, during the cell culture, supplementing a plant lectin (such as concanavalin A) and a growth factor having interleukin-2-like activity to the culture medium. Accordingly, the present method can proliferate / activate, on a preferential basis, aβ-type T cells associated with cell-mediated immunity for cancers, immunodeficiency diseases and infectious diseases.

The invention provides an anti-depression drug, which is characterized in that a medicinal ingredient of the anti-depression drug takes dendritic cell-associated C type plant lectin-1 as a target; and through bonding, activation and / or up-regulated expression of the dendritic cell-associated C type plant lectin-1, an anti-depression effect is achieved. The dendritic cell-associated C type plant lectin-1, as a novel therapeutic drug design target, is expected to promote screening of anti-depression drugs which are based on an ingredient activating a Dectin-1 receptor.

The invention belongs to the technical field of plant somatic cell hybridization, in particular to a method for electrofusion of sugarcane protoplasts, comprising the following steps: (1) preparationof parent protoplasts; (2) protoplast inactivation; (3) the addition of protoplast fusion inducer: agglutinating and binding plants to the surface of one parent protoplast and binding biotin to the surface of another parent protoplast; (4) protoplast fusion. The invention utilizes the principle that plant lectin can combine with biotin, plant agglutination and biotin binding to the surface of thetwo parent protoplasts. The two parental protoplasts could be fused by lectin and biotin to improve one-to-one fusion rate. The hybrid progeny possessed the genes of ROC22 sugarcane with high yield, high sugar content and high drought tolerance, and also possessed the genes of GT28 sugarcane with high sugar content and cold tolerance.

The invention discloses a separation and purification process of high-activity phytolectin, which comprises the following steps: fully soaking beans with pure water, peeling, mixing the peeled beans with a buffer solution, and carrying out wall breaking treatment to obtain slurry; fully stirring the slurry to fully dissolve out PHA; preliminarily removing impurities to obtain a PHA crude extract; and purifying by using SP ion exchange chromatography and DEAE ion exchange chromatography in sequence to obtain a PHA-L protein solution. The separation and purification process of some examples is simple and convenient to operate, impurities can be effectively removed, the activity of the phytolectin can be reserved, and the high-purity and high-activity phytolectin can be obtained.

The invention relates to a glucose-responsive nitrile polyphosphine hydrogel and a method for preparing the same. The method utilizes interaction between nitrile polyphosphine containing glucose side groups and lectin concanavalin A (Concanavalin A, Con A) to obtain a hydrogel system with different crosslinking degrees and water contents through the proportion increase of the glucose side groups and the selection of a second proper substituting group and a third proper substituting group and other means; and the nitrile polyphosphine hydrogel system has glucose responsiveness, biocompatibility and biodegradability, and can be used for intelligent release of insulin.

The invention discloses a human lectin / human lectin-like chip for glycosylation detection in the field of biological sciences and a preparation method, which is constructed based on recombinant human lectin / human lectin-like protein. The recombinant proteins are 60 kinds of human lectin / human lectin-like proteins capable of recognizing and binding different sugar groups. Compared with the traditional plant lectin chip, the human lectin / human lectin chip has more specific recognition ability and stronger binding ability to complex glycoforms of higher vertebrate samples. Human lectin / human lectin-like chips provide a new technology platform for glycomics research and can be widely used in glycosylation research of humans or other mammals.

The subject invention concerns materials and methods for treating or preventing disease and conditions associated with various sulfatase enzymes that are defective or that are not properly expressed in a person or animal. In one embodiment, the disease is Sanfilippo A (MPS-IIIA) disease. The subject invention also concerns materials and methods for treating or preventing multiple sulfatase deficiency (MSD) in a person or animal. Compounds of the invention include a fusion protein comprising i) a mammalian sulfatase, or an enzymatically active fragment or variant thereof, and ii) a plant lectin or a binding subunit thereof. In a specific embodiment, the mammalian sulfatase is a human sulfatase, or an enzymatically active fragment or variant thereof. Polynucleotides encoding the fusion proteins are also contemplated for the subject invention. The subject invention also concerns materials and methods for producing proteins of the invention.

The invention discloses a method for rapidly detecting toxicity of beans. The method comprises the following steps of processing the beans into extract liquid, measuring the content of lectin in the extract liquid, calculating the toxicity level of the beans by utilizing a multi-element regression equation Y2=30.837+4.5X1, wherein X1 is the content of the plant lectin, and Y2 represents the growth influencing rate of mouse cells. The Y2 value is solved by measuring the lectin of new beans under the same condition, and the toxicity level of the beans can be judged. The method is high in systematicness and comprehensiveness; the method is simple to operate, wide in applicability and capable of helping the evaluation of toxicity of other plants; the toxicity of unknown beans can be judged; the accuracy for predicting the toxicity level of the beans is high.

The invention relates to an artificial casing rich in phytolectin. The casing comprises the following components in percentage by weight: 30-40 parts of animal endothelium with a fine grinding mesh number of 200-400 meshes, 10-15 parts of soybeans, 15-20 parts of jackfruit seeds, 4-8 parts of sodium carboxymethyl cellulose, 5-10 parts of sweet potato powder, 2-3 parts of D-sodium isoascorbiate, 1-1.5 parts of nicotinamide, 1-2 parts of lycium barbarum polysaccharide, 3-6 parts of polyoxyethylene sorbitan fatty acid ester, 0.5-1.5 parts of Hydroxypropyl distarch phosphate, 0.5-1 part of glutaraldehyde, 1-3 parts of alpha-tocopherol, 1-2 parts of sodium erythorbate, 1-2 parts of ester of adipic acid and 2,3-butanediol, 3-5 parts of epoxidized olive oil, and 1-1.5 parts of 1,4-dibutyl-6-(1-ethyl pentadecyl) phenol.

The invention discloses the use of a phytohemagglutinin PHA-L in the preparation of anti-coronavirus drugs. The present invention has been verified by experiments and found that the phytohemagglutinin PHA-L has better anti-highly pathogenic coronavirus activity, and can simultaneously Inhibition of SARS-CoV-2, SARS-CoV, MERS-CoV virus activity, shows that the phytohemagglutinin PHA-L can be used in the preparation of anti-coronavirus drugs, and has important prevention and / or treatment of high pathogenicity Application prospects of coronavirus infection.

The invention discloses a method for industrially preparing a white kidney bean α-amylase inhibitor, which belongs to the field of preparation of plant active ingredients. In the method of the present invention, white kidney beans are dry-peeled, dry-crushed, and sieved to make soybean powder, then the soybean powder is extracted with water, centrifuged, and the slurry is collected, and the slurry is fully enzymolyzed with β-amylase to obtain the enzyme The enzymolysis liquid is filtered with a ceramic membrane, the obtained filtrate is ultrafiltered with an 80-150kDa ultrafiltration membrane, the permeate is ultrafiltered with a 15-30kDa ultrafiltration membrane, and the retentate is spray-dried to obtain white Kidney bean alpha-amylase inhibitor. The white kidney bean α-amylase inhibitor product prepared by the present invention not only has high α-amylase inhibitor activity, does not contain starch, does not have plant lectin and trypsin inhibitor activity, has reliable physiological efficacy and safety, and is prepared The process is green and environmentally friendly, adapts to the requirements of modern industrial production, and has significant economic and social benefits.

The invention relates to the field of natural medicine, in particular to compound phytolectin and a preparation method and application thereof. The compound phytolectin is prepared from pseudo-ginseng, eucommia ulmoides, root of kudzu vine, rehmannia, root of red-rooted salvia, kelp and silverweed cinquefoil root leaves, wherein the compound phytolectin contains the components of salvianic acid, salvia miltiorrhiza flavones, notoginsenoside, rehmannia saponin, rehmannin, laminaran, pueraria flavones and eucommia ulmoides terpene. Pharmacological experiments prove that the compound phytolectinhas an ideal therapeutical effect for hypertension, when the compound phytolectin is cooperatively used with hypotensive drugs, the antihypertensive efficacy is further strengthened and is obviously superior to exclusive use of hypotensive drugs, and the toxic and side effects such as edema of hypotensive drugs after cooperative use are greatly reduced. Moreover, the compound phytolectin is a natural preparation, is safe and reliable to use, is applicable for various types of hypertension patients, and is extremely suitable for current clinical requirements.

Methods for preferentially delivering an active agent intracellularly to a reservoir cell that is infected with or susceptible to infection with an infectious agent, such as HIV. The active agent is part of a lipid-active agent complex that has a targeting ligand, such as a CTL / CTLD receptor-specific anchor, on its outer surface. Targeting systems are also disclosed. Such targeting systems are comprised of lipid-active agent complexes that contain targeting ligands, such as fucose and polyfucose derivatives, on their outer surfaces. The active agents include plant lectins, such as Con-A and MHL, and other drugs. Such methods and targeting systems may be used in the treatment of HIV and other infectious and non-infectious diseases.

The invention discloses a preparation method of canavaline polymer hydrogel, and relates to the technical field of polymer materials. The preparation method comprises the following steps that canavaline A is dissolved in a buffer solution, then mannose monomers, photodiacetamide, acrylamide and an initiator are added into the solution, and the canavaline polymer hydrogel is prepared after heating polymerization. The structural formula of the mannose monomer is shown in the specification, and the structural formula of the photodiacetamide is shown in the specification. The preparation method has the beneficial effects that the giant protein supramolecular monomer is constructed by combining the plant lectin tetramer canavaline and the double-bond modified mannose monomer, so that the polymer hydrogel has good adhesion performance and biocompatibility, and has good application prospects in the fields of drug release, tissue engineering and the like.

Described is a matrix to identify mother's milk missing fucosyltransferase-2 (FUT2) dependent glycans which comprise a line of a glycan binding protein such as a lectin or antibody suitable to bind 2′fucosyl-glycans and a line of a positive control to bind a mother's milk protein. For instance, this matrix is porous and allows for transport by capillary force of compounds of mother's milk such as glycoproteins. Especially, the glycan binding protein is the plant lectin from Ulex europaeus. A diagnostic kit comprising one or more of such matrices and a device suitable to receive such a matrix provided with a milk application window and a read-out window has been described as well. Finally a kit-of-parts comprising such a diagnostic kit and one or more feeding doses of 2′fucosyl-glycans has been disclosed.

The invention relates to a DNA fragment having an insecticidal effect and agricultural application of the DNA fragment, belonging to the technical field of biological transgenosis. The DNA fragment having the insecticidal effect consists of a signal peptide sequence, a toxin protein sequence, a phytolectin sequence and an auxiliary sequence; the DNA fragment having the insecticidal effect is formed by linking the spider toxin sequence and the phytolectin sequence which take an insecticidal effect in a special mode and by adding the auxiliary sequence to increase expression quantity, and the formed DNA fragment has a positive effect in the aspects of pest repelling and control. The agricultural application mode of the DNA fragment includes the follows: DNA is transcribed and translated into fusion protein, or a polynucleotide composition, which is constructed by the DNA fragment and a plant promoter, is transformed and expressed in a plant body so as to form a resistant plant.

The present invention discloses a plant lectin succ-Con A for treating coronavirus infection and its application. The present invention finds for the first time that the plant lectin succ-Con A targets both SARS-CoV-2 and SARS-CoV-2 mutant strains, SARS‑CoV and MERS‑CoV coronavirus strains have broad-spectrum antiviral effects and can be used as broad-spectrum antiviral preparations or pharmaceutical active ingredients, providing new ideas for the prevention and treatment of coronavirus infections.